Macrophage PRMT9 Limits Myocardial Infarction Damage in Mice

The clinical management of acute myocardial infarction has evolved significantly, yet ischemia-reperfusion injury (tissue damage caused when blood supply returns to the heart after a period of oxygen deprivation) remains a primary driver of post-ischemic morbidity [1, 2]. Following the initial event, the myocardium undergoes an intense inflammatory response where macrophages play a dual role, transitioning between pro-inflammatory M1-like states that exacerbate tissue damage and reparative M2-like states [3, 4]. Excessive activation of the Janus kinase and signal transducer and activator of transcription (JAK-STAT) system, a signaling pathway that communicates external chemical signals to the cell nucleus, can lead to persistent inflammation and adverse ventricular remodeling [5, 2]. Recent advances in cardiovascular epigenetics (the study of chemical modifications that regulate gene expression without altering the DNA sequence) suggest that post-translational protein methylation is a critical regulator of these inflammatory phenotypes [6, 3]. A new study identifies that protein arginine methyltransferase 9 (PRMT9) facilitates the symmetric dimethylation and autophagic degradation of STAT1, a process that suppressed excessive M1-like macrophage responses and reduced infarct size in experimental models [3]. Understanding these enzymatic triggers is essential for developing targeted interventions to transition the heart from a destructive to a reparative state.